First-in-Class bs-Ab
IDC001 is designed to treat cancers that express high level of PAUF and CTHRC1


IDC001 exploits a combined anti-tumor mechanism of PBP1510 and PBP1710. It is designed to treat cancers that express relatively high level of PAUF and CTHRC1 and have developed resistance to first-line treatments, such as pancreatic cancer, liver cancer, and ovarian cancer.

Mechanism of Action

Highly aggressive cancers use multiple mechanisms (overexpression of PAUF and CTHRC1) to secure rapid proliferation, early metastasis, and immune evasion. Patients with high levels of both PAUF and CTHRC1 tend to have the poorest rate of survival.


[1] CTHRC1 may serve as a prognostic biomarker for hepatocellular carcinoma. Onco Targets Ther (2019).

[2] Elevated expression of PAUF is associated with poor prognosis and chemoresistance in epithelial ovarian cancer. Sci Rep (2018).

[3] Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis. PLOS ONE (2013).

[4] Efficient targeting and tumor retardation effect of PAUF-specific RNA replacement in pancreatic cancer mouse model. Cancer Lett (2014).

[5] PAUF, a novel up-regulated secretory protein in pancreatic ductal adenocarcinoma. Cancer Sci  (2009).

Phase of Clinical Research

Pipeline : IDC 001

Category : bs-Ab (bispecific antibody)

Indication : Pancreatic Cancer, Ovarian Cancer

Development Stage

  • Cloning 20% 20%